Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Cell-free treatment reduces brain damage and improves recovery after stroke in mice (opens in a new tab)

medicalxpress.com · 2026-10-06

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 2 supported
  • 4 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Two of six claims match the study. This overall rating is based only on the claims we could check. Four claims the study doesn't address.

  • 2 supported
  • 4 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6Not coveredIn vitro, the secretome improved microglial viability, reduced oxidative stress, restored mitochondrial function, and shifted microglia from a pro-inflammatory M1 state toward an M2 phenotype.View evidenceHide evidence

Why this verdict

The abstract-level profile supports an in vitro CoCl2-hypoxic BV2 microglia model and reports microglial phenotype/inflammatory signaling modulation, with a shift toward an M2-associated profile. However, the specific in vitro claims about improved microglial viability, reduced oxidative stress, and restored mitochondrial function are not provided in the abstract profile, and the abstract does not clearly disaggregate all BV2 readouts from in vivo tissue findings.

1

Study evidence

Proteomic profiling of the hDPSC secretome identified antioxidant-associated proteins (SOD2, GSR, GSTP1) and microglial phenotype–related candidates (GRN, CSF1, LRP1).

“we investigated its therapeutic effects in a photothrombotic mouse model of ischemic stroke and CoCl2-induced hypoxic BV2 microglial cells.”
Claim 2 of 6Not coveredIn mice, the secretome significantly reduced infarct volume and neuronal apoptosis, mitigated oxidative stress and inflammation, and activated Nrf2/HO-1 signaling while suppressing TLR4, NOX1–NOX4 and NF-κB signaling.View evidenceHide evidence

As statedsignificantly

Why this verdict

The profile supports reduced infarct volume, attenuated neuronal apoptosis/ROS, reduced NF-κB-associated inflammatory signaling, and related redox/inflammatory pathway findings in mice. But the abstract profile does not verify the word 'significantly,' nor the specific Nrf2/HO-1 activation, TLR4 suppression, or NOX1–NOX4 suppression claims. Those details may require full-text evidence.

1

Study evidence

hDPSC secretome treatment reduced infarct volume and was associated with improved motor coordination, spatial learning and memory, contextual memory, and anxiety-like behavior in a photothrombotic mouse model of ischemic stroke.

“we investigated its therapeutic effects in a photothrombotic mouse model of ischemic stroke”
2

Study evidence

hDPSC secretome treatment attenuated stroke-increased neuronal apoptosis in cortex and hippocampus.

“attenuated stroke-increased neuronal apoptosis, neuronal ROS accumulation, and NF-κB-associated inflammatory signaling in the cortex and hippocampus”
Claim 3 of 6Not coveredThe article says treated stroke-injured mice showed improved balance, motor coordination, sensorimotor responses, spatial learning, working memory, associative memory, and less post-stroke anxiety behavior.View evidenceHide evidence

Why this verdict

The profile supports improved motor coordination, spatial learning and memory, contextual memory, and anxiety-like behavior after treatment. It does not verify the more granular behavioral endpoints listed in the story—balance, sensorimotor responses, working memory, and associative memory as distinct outcomes—at abstract depth. Contextual memory may overlap with associative memory, but the exact battery and domains are not fully verifiable from the supplied profile.

1

Study evidence

hDPSC secretome treatment reduced infarct volume and was associated with improved motor coordination, spatial learning and memory, contextual memory, and anxiety-like behavior in a photothrombotic mouse model of ischemic stroke.

“we investigated its therapeutic effects in a photothrombotic mouse model of ischemic stroke”
Claim 4 of 6Not coveredThe paper is published in Advanced Science and is identified as 'Human Dental Pulp Stem Cell Secretome Restores Ischemic Stroke–Impaired Motor and Cognitive Functions by Reprogramming Redox and Inflammatory Signaling' with DOI 10.1002/advs.76717.View evidenceHide evidence

Why this verdict

The supplied paper profile does not include journal, title, DOI, or author metadata sufficient to verify publication in Advanced Science or DOI 10.1002/advs.76717. This bibliographic claim is therefore not verifiable from the provided abstract-level profile.

Claim 5 of 6SupportedA study led by Won-Jae Kim at Chonnam National University found that a human dental pulp stem cell (hDPSC) secretome may improve recovery after ischemic stroke.View evidenceHide evidence

Why this verdict

The core headline claim that hDPSC secretome may improve post-ischemic-stroke recovery is supported at abstract level: the paper profile reports reduced infarct volume and improved motor/cognitive/anxiety-like outcomes in a photothrombotic mouse model. The author/institution attribution is not contained in the supplied profile, but the scientific claim is hedged and preclinical, so it does not overstate the abstract-level evidence.

1

Study evidence

hDPSC secretome treatment reduced infarct volume and was associated with improved motor coordination, spatial learning and memory, contextual memory, and anxiety-like behavior in a photothrombotic mouse model of ischemic stroke.

“we investigated its therapeutic effects in a photothrombotic mouse model of ischemic stroke”
Claim 6 of 6SupportedThe article says the study was done in a photothrombotic mouse model and examined how the hDPSC secretome affected delayed neuronal injury and functional recovery after stroke.View evidenceHide evidence

Why this verdict

The paper profile supports that the study used a photothrombotic mouse model and examined hDPSC secretome effects on post-stroke injury and functional recovery, including infarct volume, apoptosis/ROS/inflammatory signaling, and behavioral recovery. The specific phrase 'delayed neuronal injury' is not detailed in the abstract profile, but the broader claim is consistent with the profiled aims and outcomes.

1

Study evidence

hDPSC secretome treatment reduced infarct volume and was associated with improved motor coordination, spatial learning and memory, contextual memory, and anxiety-like behavior in a photothrombotic mouse model of ischemic stroke.

“we investigated its therapeutic effects in a photothrombotic mouse model of ischemic stroke”
2

Study evidence

hDPSC secretome treatment attenuated stroke-increased neuronal apoptosis in cortex and hippocampus.

“attenuated stroke-increased neuronal apoptosis, neuronal ROS accumulation, and NF-κB-associated inflammatory signaling in the cortex and hippocampus”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Proteomic characterization of the hDPSC secretome identified antioxidant-associated proteins and microglial phenotype-related candidate proteins, including SOD2, GSR, GSTP1, GRN, CSF1, and LRP1.

    The story broadly mentions redox and inflammatory mechanisms but does not appear to report the secretome proteomic characterization or the named candidate proteins, which are a material part of the paper's mechanistic/product-characterization evidence.

    From Proteomic profiling of hDPSC secretome

  • Brain/tissue proteomic pathway analysis reported coordinated changes in oxidative phosphorylation, inflammatory responses, calcium signaling, SNARE-associated vesicular transport, and ROBO–Rho cytoskeletal remodeling.

    The story mentions redox and inflammatory signaling and neural repair at a high level, but it does not reflect the specific omics/pathway-analysis component or the named pathways beyond broad inflammation/redox framing.

    From brain tissue proteomics

  • Limitation: the abstract does not provide sample sizes, effect sizes, statistical values, dosing, route, timing, blinding, or replication details needed to assess internal validity and magnitude.

    The story reports several outcomes and uses terms such as 'significantly,' but its listed caveats do not mention that the abstract-level evidence lacks quantitative and methodological details.

    From photothrombotic_mouse_model_with_hDPSC_secretome_treatment; In vivo photothrombotic mouse ischemic stroke model; post-st

  • Limitation: the BV2 CoCl2 model is a simplified in vitro system; BV2 is an immortalized microglial line and CoCl2 is a chemical hypoxia proxy.

    The story notes that in vitro work was used, but it does not mention the interpretation-changing limitations of the specific BV2/CoCl2 model.

    From In vitro BV2 microglia; CoCl2 chemical hypoxia; hDPSC secretome treatment

5 things the story did carry across
  • Primary in vivo finding: hDPSC secretome was tested in a photothrombotic mouse model of ischemic stroke and was associated with reduced infarct volume and improved functional outcomes.
  • In vivo mechanistic phenotyping: treatment attenuated neuronal apoptosis, neuronal ROS accumulation, NF-κB-associated inflammatory signaling, shifted microglial markers toward an M2-associated profile, and improved neurogenesis/vascular/synaptic organization.
  • In vitro CoCl2-induced hypoxic BV2 microglial-cell experiments were used to test direct microglial responses to the secretome.
  • Limitation: evidence is preclinical and comes from a single photothrombotic mouse model, with translatability to humans not addressed in the abstract.
  • Limitation: mechanistic and proteomic findings are associative; causal mediation between specific molecular changes and functional recovery is not established in the abstract.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

5

Evidence read

study summary

Lead result

in vivo animal

1Lead resultin vivo animalTest whether human dental pulp stem cell (hDPSC) secretome improves functional recovery after ischemic stroke in vivo and link benefits to reduced infarct/injury and improved motor/cognitive outcomes.photothrombotic mouse model with hDPSC secretome treatmentExpand

In plain English

In a photothrombotic mouse model of ischemic stroke, treatment with human dental pulp stem cell (hDPSC) secretome reduced infarct volume and was associated with improved motor coordination, spatial learning and memory, contextual memory, and anxiety-like behavior. The treatment was also reported to attenuate neuronal apoptosis, neuronal ROS accumulation, and NF-κB–associated inflammatory signaling, shift microglial marker expression toward an M2-associated profile, and improve hippocampal neurogenesis, vascular remodeling, and synaptic organization. Proteomic profiling identified antioxidant-associated proteins (e.g., SOD2, GSR, GSTP1) and microglial phenotype–related candidates (e.g., GRN, CSF1, LRP1) and revealed coordinated changes in pathways linked to oxidative phosphorylation, inflammatory responses, calcium signaling, vesicular transport, and cytoskeletal remodeling. The authors present these molecular and cellular changes as associated with the observed functional and lesion-size improvements, supporting the hDPSC secretome as a candidate cell-free therapy for post-stroke recovery.

Key findings

  • hDPSC secretome treatment reduced infarct volume and was associated with improved motor coordination, spatial learning and memory, contextual memory, and anxiety-like behavior in a photothrombotic mouse model of ischemic stroke.
  • Treatment attenuated neuronal apoptosis, reduced neuronal ROS accumulation, and decreased NF-κB–associated inflammatory signaling in cortex and hippocampus; microglial marker expression shifted toward an M2-associated profile.
“we investigated its therapeutic effects in a photothrombotic mouse model of ischemic stroke”
What this piece can’t prove
  • Mechanistic and proteomic findings are described as associated with improved outcomes; the abstract does not establish causal mediation.

2 further details could not be confirmed from the summary.

2in vivo animalDefine molecular/cellular mechanisms in the post-stroke brain associated with hDPSC secretome treatment (redox balance, neuronal apoptosis/ROS, NF-κB inflammation, microglial phenotype, neurogenesis, vascular remodeling, synaptic organization).In vivo photothrombotic mouse ischemic stroke model; post-stroke brain tissue phenotypingExpand

In plain English

In a photothrombotic mouse model of ischemic stroke, treatment with human dental pulp stem cell (hDPSC) secretome was reported to reduce stroke-associated neuronal apoptosis and neuronal ROS accumulation, attenuate NF-κB–associated inflammatory signaling, shift microglial marker expression toward an M2-associated profile, and improve hippocampal neurogenesis, vascular remodeling, and synaptic organization in cortex and hippocampus. These tissue-level molecular and cellular changes were presented as mechanisms associated with post-stroke functional recovery.

Key findings

  • hDPSC secretome treatment attenuated stroke-increased neuronal apoptosis in cortex and hippocampus.
  • hDPSC secretome reduced neuronal ROS accumulation in cortex and hippocampus after stroke.
“attenuated stroke-increased neuronal apoptosis, neuronal ROS accumulation, and NF-κB-associated inflammatory signaling in the cortex and hippocampus”
What this piece can’t prove
  • Summary is based on abstract text only; the abstract lacks assay-level details (methods, timepoints, sample sizes, blinding, statistical measures) needed to fully appraise internal validity.

3 further details could not be confirmed from the summary.

3in vivo animalDefine molecular/cellular mechanisms in the post-stroke brain associated with hDPSC secretome treatment (redox balance, neuronal apoptosis/ROS, NF-κB inflammation, microglial phenotype, neurogenesis, vascular remodeling, synaptic organization).brain tissue proteomicsExpand

In plain English

Proteomic profiling of post-stroke mouse brain after hDPSC secretome treatment identified antioxidant-associated proteins (SOD2, GSR, GSTP1) and microglial phenotype-related candidates (GRN, CSF1, LRP1), and reported coordinated pathway-level changes in oxidative phosphorylation, inflammatory responses, calcium signaling, SNARE-associated vesicular transport, and ROBO–Rho-associated cytoskeletal remodeling.

Key findings

  • Proteomic profiling identified antioxidant-associated proteins (SOD2, GSR, GSTP1) and microglial phenotype–related candidates (GRN, CSF1, LRP1) in post-stroke brain after hDPSC secretome treatment.
  • Pathway-level proteomic analyses reported coordinated changes in oxidative phosphorylation, inflammatory responses, calcium signaling, SNARE-associated vesicular transport, and ROBO–Rho-associated cytoskeletal remodeling associated with hDPSC secretome treatment.
“Proteomic analyses further identified coordinated changes in pathways related to oxidative phosphorylation, inflammatory responses, calcium signaling, SNARE-associated vesicular transport, and ROBO-Rho-associated cytoskeletal remodeling.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

4in vitroCharacterize the hDPSC secretome composition and identify candidate antioxidant and microglia-related factors via proteomics.Proteomic profiling of hDPSC secretomeExpand

In plain English

Proteomic profiling of the human dental pulp stem cell (hDPSC) secretome (cell-free product) identified antioxidant-associated proteins (SOD2, GSR, GSTP1) and candidate proteins linked to microglial phenotype regulation (GRN, CSF1, LRP1).

Key findings

  • Proteomic profiling of the hDPSC secretome identified antioxidant-associated proteins (SOD2, GSR, GSTP1) and microglial phenotype-related candidate proteins (GRN, CSF1, LRP1).
“Proteomic profiling identified antioxidant-associated proteins, including SOD2, GSR, and GSTP1, and microglial phenotype-related candidates, including GRN, CSF1, and LRP1.”
What this piece can’t prove
  • Abstract does not specify whether identified proteins are free soluble factors versus vesicle-associated, nor does it describe validation experiments for protein identities or functions.

2 further details could not be confirmed from the summary.

5in vitroTest direct effects of hDPSC secretome on hypoxia/inflammation-related microglial responses in an in-vitro hypoxic BV2 microglia model.In vitro BV2 microglia; CoCl2 chemical hypoxia; hDPSC secretome treatmentExpand

In plain English

The study used a CoCl2-induced chemical hypoxia model in BV2 microglial cells to test direct effects of human dental pulp stem cell (hDPSC) secretome on hypoxia- and inflammation-related microglial responses. Proteomic characterization of the secretome identified antioxidant-associated proteins (SOD2, GSR, GSTP1) and microglial phenotype–related candidates (GRN, CSF1, LRP1). Treatment with the hDPSC secretome was associated with modulation of inflammatory signaling and a shift in microglial marker expression toward an M2-associated profile; inflammatory signaling changes included attenuation of NF-κB–associated pathways as reported in the paper.

Key findings

  • Proteomic profiling of the hDPSC secretome identified antioxidant-associated proteins (SOD2, GSR, GSTP1) and microglial phenotype–related candidates (GRN, CSF1, LRP1).
  • hDPSC secretome treatment was associated with attenuation of NF-κB–associated inflammatory signaling.
“we investigated its therapeutic effects in a photothrombotic mouse model of ischemic stroke and CoCl2-induced hypoxic BV2 microglial cells.”
What this piece can’t prove
  • BV2 is an immortalized microglial cell line and CoCl2 is a chemical hypoxia proxy; both are simplified models of in vivo microglial responses to ischemia and have known limitations for generalizability.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

Human Dental Pulp Stem Cell Secretome Restores Ischemic Stroke-Impaired Motor and Cognitive Functions by Reprogramming Redox and Inflammatory Signaling.

Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026

Deep dive in Tessa (opens in a new tab)Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 15 candidate papers

SelectedOpen access

Human Dental Pulp Stem Cell Secretome Restores Ischemic Stroke-Impaired Motor and Cognitive Functions by Reprogramming Redox and Inflammatory Signaling.

Advanced Science (Weinheim, Baden-Wurttemberg, Germany) · 2026 · PubMed, Europe PMC, Crossref

Tessa (opens in a new tab)Source (opens in a new tab)
Candidate

Review for "Dental Pulp Mesenchymal Stem Cell-Secretome Gel Reverse Areca Nut Induced Oral Submucous Fibrosis in Mice: A Pilot Study"

2025 · Crossref

Source (opens in a new tab)

And 9 more candidates considered.